Non-Hodgkin Lymphoma: Diagnostic Workup and Treatment Strategy
Diagnostic Workup
An excisional or incisional lymph node biopsy is mandatory for initial diagnosis—fine needle aspiration (FNA) or core needle biopsy alone is insufficient. 1, 2 Only when lymph nodes are inaccessible should a combination of core biopsy plus FNA with comprehensive ancillary testing be considered, though this remains suboptimal for histologic grading.
Essential Pathologic Evaluation
The diagnostic foundation requires 1, 2:
- Hematopathology review of all slides with at least one representative paraffin block
- Immunophenotyping panel (paraffin section):
- CD20, CD3, CD5, CD10, CD45, BCL2, BCL6, Ki-67, IRF4/MUM1
- Flow cytometry for cell surface markers:
- Kappa/lambda, CD45, CD3, CD5, CD19, CD10, CD20
Essential Clinical Workup
Once diagnosis is established, complete the following 1, 2:
- Physical examination focusing on all node-bearing areas (including Waldeyer's ring), liver/spleen size
- Performance status assessment and documentation of B symptoms (fever, night sweats, weight loss)
- Laboratory studies:
- CBC with differential and platelets
- Comprehensive metabolic panel
- LDH (critical prognostic marker)
- Beta-2-microglobulin
- Hepatitis B testing (surface antigen and core antibody minimum; add e-antigen if risk factors present) 1—this is non-negotiable before rituximab-based therapy due to reactivation risk
- Imaging: Chest/abdominal/pelvic CT scans 1
Useful in Selected Circumstances
Additional workup depends on subtype and presentation 2:
- Molecular/cytogenetic studies: BCL2, BCL6, MYC rearrangements; t(14;18), t(8;14) by FISH
- Bone marrow biopsy: Essential for certain aggressive subtypes (e.g., DLBCL with specific features)
- Lumbar puncture: Required if paranasal sinus, testicular, epidural involvement, bone marrow with large cell lymphoma, HIV-associated lymphoma, or ≥2 extranodal sites 2
- PET-CT: Increasingly important for staging and response assessment, though not universally required at diagnosis
Critical Diagnostic Pitfalls
The pathologist must provide specific immunophenotypic characterization—a "germinal center phenotype" alone does not equal diffuse large B-cell lymphoma and may represent follicular lymphoma 2. Rebiopsy is mandatory if initial material is nondiagnostic 1.
Treatment Strategy Framework
Treatment selection depends on three key factors: histologic subtype, stage, and prognostic indices 3, 4.
Subtype-Based Natural History Classification
NHL subtypes fall into behavioral categories that dictate urgency 3:
- Indolent (e.g., follicular lymphoma grades 1-2): Slower progression, often watch-and-wait appropriate
- Aggressive (e.g., DLBCL): Requires immediate treatment
- Acute leukemia-like (e.g., Burkitt): Medical emergency requiring urgent intervention
- Viral-associated: Special considerations for immunosuppression
Treatment Principles by Major Subtypes
For Diffuse Large B-Cell Lymphoma (DLBCL):
The standard remains R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) for 6 cycles in most patients 2, 5, 4. For limited stage disease (stage I-II), 3-4 cycles of R-CHOP followed by involved-site radiation therapy is an acceptable alternative 2, 6.
For Follicular Lymphoma:
Initial management should include rituximab-based therapy when treatment is indicated 2. The combination of R-bendamustine has shown high efficacy with reduced toxicity compared to R-CHOP and represents a preferred option 5. Asymptomatic patients with low tumor burden may be observed without immediate treatment.
For Mantle Cell Lymphoma:
- Younger patients: Intensive therapy with AraC-containing regimens plus autologous stem cell transplantation 5
- Older patients: R-CHOP with rituximab maintenance therapy 5
Special Circumstances Requiring Modified Approach
- Testicular lymphoma: After chemotherapy completion, contralateral testis radiation (30-36 Gy) is mandatory 2
- CNS prophylaxis sites: Intrathecal chemotherapy for paranasal sinus, testicular, epidural, or bone marrow involvement with large cell lymphoma 2
- Cardiac dysfunction: Avoid anthracyclines; consider alternative regimens with more frequent cardiac monitoring if anthracyclines necessary 2
- Hepatitis B positive: Prophylactic antiviral therapy required; consult gastroenterology for viral load monitoring 2
Radiation Therapy in Modern Era
Involved-site radiation therapy (ISRT) has replaced extended-field techniques 7. The clinical target volume is now limited to detectable nodal involvement at presentation when combined with systemic therapy. For indolent NHL treated with radiation alone, larger fields remain appropriate 7.
Post-Treatment Surveillance
Long-term monitoring is essential for 8, 4:
- Disease recurrence: More common in aggressive subtypes
- Histologic transformation: Particularly follicular lymphoma transforming to DLBCL
- Late treatment effects: Secondary malignancies, cardiac toxicity, infertility
Relapsed/Refractory Disease
Second-line therapy options include clinical trials, alternative chemotherapy regimens (GDP, GemOx, DA-EPOCH, lenalidomide), with or without rituximab depending on duration of initial remission 2. High-dose therapy with autologous stem cell rescue is standard for chemotherapy-sensitive relapse in appropriate candidates 2.
The key principle: Accurate histologic diagnosis drives all subsequent management decisions, and treatment should be expedited in experienced centers with multidisciplinary teams 9, 4.